These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6131948)

  • 1. Dopamine receptor antagonism by the novel antianxiety drug, buspirone.
    McMillen BA; Matthews RT; Sanghera MK; Shepard PD; German DC
    J Neurosci; 1983 Apr; 3(4):733-8. PubMed ID: 6131948
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug.
    McMillen BA; Mattiace LA
    J Neural Transm; 1983; 57(4):255-65. PubMed ID: 6140299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover.
    Meltzer HY; Simonovic M; Fang VS; Gudelsky GA
    Psychopharmacology (Berl); 1982; 78(1):49-53. PubMed ID: 6128756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of apomorphine and bradykinin on uptake and release of dopamine in vitro by striatal synaptosomes of the rat.
    Borawska M; Wiśniewski K
    Pol J Pharmacol Pharm; 1982; 34(1-3):79-84. PubMed ID: 7167424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal synaptosomal tyrosine hydroxylase activity. A model system for study of presynaptic dopamine receptors.
    McMillen BA
    Biochem Pharmacol; 1982 Aug; 31(16):2643-7. PubMed ID: 6128002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The autoreceptor control of dopamine synthesis. An in vitro and in vivo comparison of dopamine agonists.
    Haubrich DR; Pflueger AB
    Mol Pharmacol; 1982 Jan; 21(1):114-20. PubMed ID: 6127616
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat.
    McMillen BA; McDonald CC
    Neuropharmacology; 1983 Mar; 22(3):273-8. PubMed ID: 6133232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic control of dopamine metabolism in the nucleus accumbens. Lack of effect of buspirone as demonstrated using in vivo voltammetry.
    Louilot A; Le Moal M; Simon H
    Life Sci; 1987 May; 40(20):2017-24. PubMed ID: 3573992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission.
    McMillen BA
    J Neural Transm; 1985; 64(1):1-12. PubMed ID: 2866230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic effects of buspirone, a novel anxiolytic agent.
    Cimino M; Ponzio F; Achilli G; Vantini G; Perego C; Algeri S; Garattini S
    Biochem Pharmacol; 1983 Mar; 32(6):1069-74. PubMed ID: 6838654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of haloperidol on dopamine synthesis and tyrosine hydroxylase in striatal synaptosomes.
    Kapatos G; Zigmond MJ
    J Pharmacol Exp Ther; 1979 Mar; 208(3):468-75. PubMed ID: 34711
    [No Abstract]   [Full Text] [Related]  

  • 12. Subchronic buspirone, mesulergine, and ICS 205-930 lack effects on D1 and D2 dopamine binding in the rat striatum during chronic haloperidol treatment.
    Young KA; Zavodny R; Hicks PB
    J Neural Transm Gen Sect; 1991; 86(3):223-8. PubMed ID: 1837997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of noncholinergic drugs on rat striatal acetylcholine levels.
    McGeer PL; Grewaal DS; McGeer EG
    Brain Res; 1974 Nov; 80(2):211-7. PubMed ID: 4154064
    [No Abstract]   [Full Text] [Related]  

  • 14. Apomorphine lowers dopamine synthesis for up to 48 h: implications for drug sensitization.
    Rodriguez M; Castro R
    Neuroreport; 1991 Jul; 2(7):365-8. PubMed ID: 1680483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical effects of buspirone, a novel psychotropic drug, on the central cholinergic system.
    Kolasa K; Fusi R; Garattini S; Consolo S; Ladinsky H
    J Pharm Pharmacol; 1982 May; 34(5):314-7. PubMed ID: 6123570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists.
    Meller E; Helmer-Matyjek E; Bohmaker K; Adler CH; Friedhoff AJ; Goldstein M
    Eur J Pharmacol; 1986 Apr; 123(2):311-4. PubMed ID: 3709668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum.
    Iversen LL; Rogawski MA; Miller RJ
    Mol Pharmacol; 1976 Mar; 12(2):251-62. PubMed ID: 4724
    [No Abstract]   [Full Text] [Related]  

  • 18. Is inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function?
    Fowler CJ; Thorell G; Andersson M; Magnusson O
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):12-9. PubMed ID: 2866447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced sensitivity of synaptosomal dopamine autoreceptors following increase in synaptosomal dopamine synthesis.
    Tissari AH
    Eur J Pharmacol; 1985 Mar; 109(3):433-4. PubMed ID: 3987811
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes of kinetic constant of striatal tyrosine hydroxylase elicited by neuroleptics that impair the function of dopamine receptors.
    Zivkovic B; Guidotti A
    Brain Res; 1974 Oct; 79(3):505-9. PubMed ID: 4153770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.